Here, we show a biocompatible alginate-based hydrogel encapsulating PLX-loaded nanoparticles (designated PLX-NP) and anti-PD-1-conjugated platelets (designated P-aPD-1) for post-surgery tumor recurrence treatment, to achieve local and sustained release of PLX and anti-PD-1 antibodies for depleting TAMs and re-activating infiltrated T cells, respectively (Fig. 1a). This evidence concerns the gene PDCD1 and neoplasm.